Recent performance snapshot

Abbott Laboratories (ABT) has seen mixed share performance recently, with the stock edging up about 0.5% in the latest session and showing a gain over the past month but declines over the past 3 months and year to date.

The latest moves come against a weak backdrop, with the share price down about 17% over the past 90 days and the 1 year total shareholder return declining roughly 33%. As a result, recent momentum looks more like a short term pause than a clear shift in sentiment.

If Abbott's recent swings have you thinking about where else capital might work hard in healthcare, it could be worth scanning 40 healthcare AI stocks.

With Abbott trading at $89.65 and showing an estimated 31% gap to analyst targets plus a modeled 36% intrinsic discount, the key question is whether this reflects undervaluation or a market that is already accounting for future growth.

Most Popular Narrative: 23.6% Undervalued

At a last close of $89.65 against a narrative fair value of about $117.29, Abbott's valuation story hinges on how durable its healthcare demand and device pipeline prove to be.

The global demographic shift toward an aging population and increasing prevalence of chronic and lifestyle-related diseases (e.g., diabetes, cardiovascular disease) is underpinning strong, recurring demand for Abbott's diagnostics, nutrition (e.g., Ensure, Glucerna), and high-growth medical device franchises, supporting revenue acceleration and enhanced operating leverage.

Curious what earnings, revenue growth and margin profile sit behind this fair value? The narrative leans on higher profitability, rising healthcare needs and a richer mix of medical technologies.

Result: Fair Value of $117.29 (UNDERVALUED)

However, there are clear pressure points, including ongoing diagnostic headwinds from lower COVID testing and pricing in China, as well as legal and regulatory risks around infant formula and devices.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

Mixed signals on valuation and business momentum can feel messy, so if you want clarity, move quickly to review the full picture, including 4 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Abbott does not fully match your priorities, do not stop here. Use the Simply Wall Street Screener to spot other opportunities that fit your style.

• Target potential value opportunities by scanning 46 high quality undervalued stocks that combine strong fundamentals with compressed valuations.
• Strengthen your income focus by reviewing 8 dividend fortresses that aim to pair higher yields with resilient cash flows.
• Prioritise stability by checking 67 resilient stocks with low risk scores that score well on financial health and business risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.